Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...

Three Motley Fool contributors believe they've found no-brainer healthcare stocks to buy in June. (Amgen): One of the best ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Chemoimmunotherapy offers greater benefits than harms as first-line treatment for older patients with NSCLC, data suggest.

These findings support the need for a phase III randomized controlled trial to definitively determine whether the addition of an antiangiogenic to a second or even a third-generation TKI provides ...

Merck’s investigational KRAS G12C inhibitor, MK-1084 shows antitumor activity in phase 1 trial: Rahway, New Jersey Monday, June 2, 2025, 14:00 Hrs [IST] Merck, known as MSD outs ...

In NSCLC cohort, the combination of ifebemtinib and garsorasib, as a dual-oral, chemotherapy-free regimen, demonstrated compelling clinical benefit including high response rates and durable efficacy, ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers (NYSE:BMY) Squibb have announced their global collaboration for the co-development and co-commercialization of BioNTech’s experimental bispecific antibody ...

In recognition of its clinical potential, LBL-024 received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) in China (October 2024), and Orphan Drug ...

Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO). This is an ASCO Meeting Abstract ...

The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others. Promising PD-1+ ...

The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was ...